When combined, a novel LSD1 inhibitor and an existing therapy enhance each other’s anti-cancer effects

A Medical University of South Carolina (MUSC) research team has developed novel compounds that show early promise at fighting the rare pediatric cancer neuroblastoma when paired with the existing anti-cancer drug bortezomib (Velcade, Takeda Oncology). The novel compounds block or inhibit an enzyme known as lysine-specific demethylase 1 (LSD1). The MUSC team, led by Patrick M. Woster, Ph.D., reports its findings in the European Journal of Medicinal Chemistry.